AR020762A1 - El uso de carnitina y resveratrol para producir una composicion para la prevencion o el tratamiento terapeutico de los trastornos cerebrales provocados porel envejecimiento y el uso de drogas neurotoxicas - Google Patents

El uso de carnitina y resveratrol para producir una composicion para la prevencion o el tratamiento terapeutico de los trastornos cerebrales provocados porel envejecimiento y el uso de drogas neurotoxicas

Info

Publication number
AR020762A1
AR020762A1 ARP990105115A ARP990105115A AR020762A1 AR 020762 A1 AR020762 A1 AR 020762A1 AR P990105115 A ARP990105115 A AR P990105115A AR P990105115 A ARP990105115 A AR P990105115A AR 020762 A1 AR020762 A1 AR 020762A1
Authority
AR
Argentina
Prior art keywords
carnitine
resveratrol
prevention
aging
produce
Prior art date
Application number
ARP990105115A
Other languages
English (en)
Spanish (es)
Original Assignee
Sigma Tau Healthscience Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Healthscience Spa filed Critical Sigma Tau Healthscience Spa
Publication of AR020762A1 publication Critical patent/AR020762A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105Plant extracts, their artificial duplicates or their derivatives
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15Vitamins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Botany (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ARP990105115A 1998-10-09 1999-10-08 El uso de carnitina y resveratrol para producir una composicion para la prevencion o el tratamiento terapeutico de los trastornos cerebrales provocados porel envejecimiento y el uso de drogas neurotoxicas AR020762A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT1998RM000636A IT1302365B1 (it) 1998-10-09 1998-10-09 Uso di carnitine e resveratrolo per produrre una composizione per laprevenzione o il trattamento terapeutico di alterazioni cerebrali

Publications (1)

Publication Number Publication Date
AR020762A1 true AR020762A1 (es) 2002-05-29

Family

ID=11406160

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990105115A AR020762A1 (es) 1998-10-09 1999-10-08 El uso de carnitina y resveratrol para producir una composicion para la prevencion o el tratamiento terapeutico de los trastornos cerebrales provocados porel envejecimiento y el uso de drogas neurotoxicas

Country Status (27)

Country Link
US (1) US6515020B1 (enExample)
EP (1) EP1117394B1 (enExample)
JP (1) JP4166951B2 (enExample)
KR (1) KR20010079981A (enExample)
CN (1) CN1323205A (enExample)
AR (1) AR020762A1 (enExample)
AT (1) ATE249823T1 (enExample)
AU (1) AU767492B2 (enExample)
BR (1) BR9915918A (enExample)
CA (1) CA2344893C (enExample)
CZ (1) CZ2001920A3 (enExample)
DE (1) DE69911441T2 (enExample)
DK (1) DK1117394T3 (enExample)
EE (1) EE200100205A (enExample)
ES (1) ES2207287T3 (enExample)
HK (1) HK1040935A1 (enExample)
HU (1) HU229364B1 (enExample)
IL (1) IL142046A0 (enExample)
IS (1) IS5896A (enExample)
IT (1) IT1302365B1 (enExample)
NO (1) NO20011693L (enExample)
PL (1) PL197342B1 (enExample)
PT (1) PT1117394E (enExample)
SK (1) SK3782001A3 (enExample)
TN (1) TNSN99186A1 (enExample)
TR (1) TR200100947T2 (enExample)
WO (1) WO2000021526A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002047193A (ja) * 2000-07-31 2002-02-12 Sunstar Inc アレルギー性皮膚炎予防または治療用組成物
WO2002038141A2 (en) * 2000-11-08 2002-05-16 Massachusetts Institute Of Technology Compositions and methods for treatment of mild cognitive impairment
BRPI0106382B1 (pt) * 2001-03-13 2017-07-11 Universidade Do Estado Do Rio De Janeiro - Uerj Process for obtaining decocts from vitis labrusca and vitis vinifera casts, process for obtaining the hydro-alcoholic extract, process for obtaining the hydro-alcoholic extract-ethyl acetate and pharmaceutical compositions
DE50111204D1 (de) * 2001-08-18 2006-11-23 Cognis Ip Man Gmbh Wirkstoffmischungen
US20070218152A1 (en) * 2002-03-12 2007-09-20 Roberto Moura Process for obtention of decoctions of Vitis labrusca and Vitis vinifera skins
US7977049B2 (en) * 2002-08-09 2011-07-12 President And Fellows Of Harvard College Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
KR100574392B1 (ko) * 2003-02-07 2006-05-02 재단법인서울대학교산학협력재단 신경보호활성을 갖는 신규 페닐환 유도체 및 이를함유하는 약학 조성물
US20060025337A1 (en) * 2003-07-01 2006-02-02 President And Fellows Of Harvard College Sirtuin related therapeutics and diagnostics for neurodegenerative diseases
EP2236131A3 (en) * 2003-07-01 2011-03-02 President and Fellows of Harvard College Sirt1 modulators for manipulating cell/organism lifespan/stress response
KR100543056B1 (ko) * 2003-11-07 2006-01-20 (주)네추럴에프앤피 신경세포 보호 활성이 있는 포도씨 추출물을 포함하는뇌질환 예방 및 치료용 조성물
US8017634B2 (en) 2003-12-29 2011-09-13 President And Fellows Of Harvard College Compositions for treating obesity and insulin resistance disorders
US20050171027A1 (en) 2003-12-29 2005-08-04 President And Fellows Of Harvard College Compositions for treating or preventing obesity and insulin resistance disorders
ES2245609B1 (es) * 2004-06-18 2007-08-16 Universidad De Barcelona Nuevo agente terapeutico para el tratamiento de la infertilidad y/o subfertilidad masculina en mamiferos.
US20060014705A1 (en) * 2004-06-30 2006-01-19 Howitz Konrad T Compositions and methods for selectively activating human sirtuins
US20060121137A1 (en) * 2004-12-07 2006-06-08 Hartle Diane K Muscadine grape pomace in the treatment of intestinal inflammation
CA2595159A1 (en) * 2005-01-13 2006-07-20 Sirtris Pharmaceuticals, Inc. Novel compositions for preventing and treating neurodegenerative and blood coagulation disorders
WO2006138418A2 (en) * 2005-06-14 2006-12-28 President And Fellows Of Harvard College Improvement of cognitive performance with sirtuin activators
EP1993522A2 (en) 2005-10-26 2008-11-26 Kao Corporation Resveratrol and/or grape leaf extract as i.a. endurance improver, anti-aging agent, muscle strength improver
FR2898493B1 (fr) * 2006-03-16 2008-08-08 Af Consulting Compositions cosmetiques, pharmaceutiques, alimentaires et veterinaires dont l'action d'activation de genes de type sirtuin permet de retarder le vieillissement des mammiferes et ses effets nefastes
US20120016037A1 (en) * 2006-07-24 2012-01-19 Frank Toppo Method for prevention and treatment of Alzheimers
EP2124985A4 (en) * 2007-01-26 2011-06-08 Univ Washington METHOD AND COMPOSITIONS FOR TREATING NERVOUS ELEMENTS
AT506014A1 (de) * 2007-10-24 2009-05-15 Karl Mag Dr Zehethofer Functional drink
MX2012014127A (es) * 2010-06-16 2013-06-28 Sigma Tau Ind Farmaceuti Acetil-carnitina para uso en un metodo para incrementar neurogenesis en tejido nervioso.
KR101327936B1 (ko) * 2011-07-06 2013-11-13 한국식품연구원 옥시레스베라트롤 이민 유도체를 유효성분으로 함유하는 뇌신경보호 효과를 가지는 조성물
CN102919943A (zh) * 2012-10-26 2013-02-13 郑全辉 保健饮品-葡藤素
CN103877170B (zh) * 2012-12-19 2015-11-04 中国医学科学院药用植物研究所 一种虎杖的乙酸乙酯提取物及其制备方法和应用
CN119424497B (zh) * 2025-01-08 2025-06-24 万邦德制药集团有限公司 一种用于防治阿尔茨海默病、皮肤光老化的组合物、制剂及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4346107A (en) * 1979-02-12 1982-08-24 Claudio Cavazza Pharmaceutical composition comprising acyl-carnitine for the treatment of impaired cerebral metabolism
IT1276225B1 (it) * 1995-10-17 1997-10-27 Sigma Tau Ind Farmaceuti Composizioni farmaceutiche contenenti l-carnitina e alcanoil l- carnitine in associazione con resveratrolo o suoi derivati utili per
IT1283967B1 (it) * 1996-03-29 1998-05-07 Sigma Tau Ind Farmaceuti Uso di l-carnitina o derivati della l-carnitina ed antiossidanti nella prevenzione e trattamento di patologie derivanti da danni ossidativi
CA2280093A1 (en) 1997-02-04 1998-08-06 John V. Kosbab Compositions and methods for prevention and treatment of vascular degenerative diseases
IT1291113B1 (it) * 1997-03-20 1998-12-29 Sigma Tau Ind Farmaceuti Composizione nutritiva terapeutica per soggetti affetti da diabete mellito
CH692837A5 (it) * 1997-07-02 2002-11-29 Lisapharma Spa Composizione farmaceutica per uso alimentare, dietetico o medicinale adatta a migliorare l'assorbimento orale dei polifenoli e particolarmente del resveratrolo presenti nell'uva e nei suoi p
US5904924A (en) * 1997-11-04 1999-05-18 Oncologics, Inc. Green nutritional powder composition
AU4084599A (en) 1998-05-18 1999-12-06 Oklahoma Medical Research Foundation Resveratrol inhibition of myeloperoxidase

Also Published As

Publication number Publication date
DE69911441D1 (de) 2003-10-23
CN1323205A (zh) 2001-11-21
AU767492B2 (en) 2003-11-13
AU6121399A (en) 2000-05-01
ATE249823T1 (de) 2003-10-15
HUP0104021A2 (hu) 2002-02-28
JP4166951B2 (ja) 2008-10-15
HU229364B1 (en) 2013-11-28
JP2002527389A (ja) 2002-08-27
CZ2001920A3 (cs) 2001-08-15
IL142046A0 (en) 2002-03-10
EE200100205A (et) 2002-06-17
ES2207287T3 (es) 2004-05-16
KR20010079981A (ko) 2001-08-22
WO2000021526A1 (en) 2000-04-20
HUP0104021A3 (en) 2003-12-29
EP1117394B1 (en) 2003-09-17
ITRM980636A1 (it) 2000-04-10
DK1117394T3 (da) 2004-01-26
PL347209A1 (en) 2002-03-25
CA2344893A1 (en) 2000-04-20
PL197342B1 (pl) 2008-03-31
NO20011693D0 (no) 2001-04-04
CA2344893C (en) 2008-07-29
IS5896A (is) 2001-03-16
NO20011693L (no) 2001-04-04
IT1302365B1 (it) 2000-09-05
HK1040935A1 (zh) 2002-06-28
DE69911441T2 (de) 2004-07-01
TNSN99186A1 (fr) 2005-11-10
US6515020B1 (en) 2003-02-04
SK3782001A3 (en) 2001-10-08
PT1117394E (pt) 2004-02-27
EP1117394A1 (en) 2001-07-25
TR200100947T2 (tr) 2001-07-23
BR9915918A (pt) 2001-08-21

Similar Documents

Publication Publication Date Title
AR020762A1 (es) El uso de carnitina y resveratrol para producir una composicion para la prevencion o el tratamiento terapeutico de los trastornos cerebrales provocados porel envejecimiento y el uso de drogas neurotoxicas
HN1998000027A (es) Arilsulfonamidas y analagos
MX9205681A (es) Aminometil-cromanos, procedimiento para su fabricacion y medicamento que los contiene.
BR9910553A (pt) Composição de liberação prolongada, processo para produção da mesma, produto de liberação prolongada, formulação farmacêutica, e, processo para tratamento de uma indicação, de um distúrbio e uma inflamação
BR9812753A (pt) Combinação farmacêutica, uso da mesma, processo para tratamento de uma doença inflamatória, e, composição farmacêutica
HN2002000275A (es) Derivados de 1,8 naftiridina y su uso para el tratamiento de diabetes y trastornos relacionados
MX9204140A (es) Nuevos derivados de analogos de taxol, procedimiento para su preparacion y composicion farmaceutica que los contienen.
DE69629273D1 (de) Zusammensetzungen enthaltend Propionyl-L-Carnitine und Hydroxyzitronensäure oder Pantothensäure
AR032132A1 (es) Composicion farmaceutica que comprende una combinacion de un compuesto de tramadol y una droga anticonvulsiva y uso de la combinacion para preparar un medicamento
BR9908877A (pt) Produto alimentìcio de multicomponentes e método para produzir e usar o mesmo
BR9913288A (pt) Composição antioxidante compreendendo acetil l-carnitina e ácido alfa-lipóico
ES2169197T3 (es) Composicion farmaceutica que comprende una alcanoil l-carnitina en combinacion con un acido graso poliinsaturado de la serie omega-3 para la prevencion y el tratamiento de trastornos del metabolismo de los lipidos.
PT659402E (pt) Composicoes contendo carotenoides e procarotenoides combinados com polifenois para a prevencao de danos devidos a uma producao anormal de radicais livres.
BR9916197A (pt) Método para o tratamento de isquemia cerebral e uso de eritropoietina ou derivados de eritropoietina para o tratamento de isquemia cerebral
ES2177843T3 (es) Composiciones que contienen l-carnitina o sus derivados y antioxidan tes.
BRPI0408863A (pt) composto, composição farmacêutica, método para tratar doenças, e, uso de um composto.
BR0210650A (pt) Tablete, e, uso do mesmo
ES2144239T3 (es) Derivados de vitamina d con sustituyentes en c-25, procedimiento para su preparacion, productos intermedios y la utilizacion para la preparacion de medicamentos.
BR0107899A (pt) Processo para produzir uma preparação de ingrediente ativo compreendendo ibuprofeno, preparação de ingrediente ativo, uso da mesma, preparação farmacêutica, uso da mesma, processo para produzir formas de dosagem sólidas, e, forma de dosagem sólida
ES2168309T3 (es) Efectos neuroprotectores primario y secundario de la flupirtina en las enfermedades neurodegenerativas.
MX9201058A (es) Derivados ciclicos de cetal, procedimiento para supreparacion y composicion farmaceutica que los contiene.
PT97300A (pt) Processo para a preparacao de esteres de acidos 1,4-di-hidropiridinocarboxilicos n-alquilados e de medicamentos que os contem
AR005468A1 (es) Nuevos derivados de benzoilguanidina, procedimientos para su preparacion y su empleo en la preparacion de medicamentos.
AR066455A2 (es) Uso de compuestos n-metil-n-[(1r)-1-fenil-2-(3r)-3-hidroxipirrolidin -1-il-=-etil]-2,2-difenilacetamida para producir un medicamento para el tratamiento de emfermedades intestinales no inflamatorias
BR9912703A (pt) Composição antioxidante, antiprolìfera, compreendendo uma carnitina e um carotenóide